BYSI BeyondSpring Inc.

11.55
+0.5  (+5%)
Previous Close 11.05
Open 11.14
52 Week Low 9.38
52 Week High 23
Market Cap $352,194,393
Shares 30,493,021
Float 10,963,858
Enterprise Value $363,104,728
Volume 44,699
Av. Daily Volume 174,357
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
Plinabulin + TAC (Trial 106)
Chemotherapy-induced neutropenia (CIN)
Phase 3
Phase 3
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
Plinabulin (Trial 103)
Non small cell lung cancer - refractory
Phase 3
Phase 3
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
Plinabulin (Trial 105)
Chemotherapy-induced neutropenia (CIN)
Phase 3
Phase 3
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Drug Pipeline

Drug Stage Notes
Plinabulin + Opdivo +Yervoy
Small-cell lung cancer (SCLC)
Phase 1/2
Phase 1/2
Phase 1/2 initiation announced October 4, 2018.

Latest News

  1. - NCCN Guideline Updates Highlight Need for Maximum CIN Prevention and Resource Allocation for COVID-19 Patients -

    - First Patient Dosed in the U.S. Avoided Grade 4 Neutropenia in Cycle 2 with Plinabulin and Pegfilgrastim, Despite Experiencing Grade 4 Neutropenia in Cycle 1 with Pegfilgrastim Alone -

    NEW YORK, Aug. 11, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the "Company" or "BeyondSpring") (NASDAQ:BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the Company has initiated an Expanded Access Program (EAP) to enable doctors across the U.S. to use BeyondSpring's late-stage asset, Plinabulin, to prevent cancer patients' chemotherapy-induced neutropenia…

    - NCCN Guideline Updates Highlight Need for Maximum CIN Prevention and Resource Allocation for COVID-19 Patients -

    - First Patient Dosed in the U.S. Avoided Grade 4 Neutropenia in Cycle 2 with Plinabulin and Pegfilgrastim, Despite Experiencing Grade 4 Neutropenia in Cycle 1 with Pegfilgrastim Alone -

    NEW YORK, Aug. 11, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the "Company" or "BeyondSpring") (NASDAQ:BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the Company has initiated an Expanded Access Program (EAP) to enable doctors across the U.S. to use BeyondSpring's late-stage asset, Plinabulin, to prevent cancer patients' chemotherapy-induced neutropenia (CIN), both alone and in combination with G-CSFs (the current standard of care), during the COVID-19 pandemic. Dr. Emad Ibrahim enrolled the first patient at Redlands Community Hospital in California on July 28, 2020.

    In response to COVID-19, the National Comprehensive Cancer Network (NCCN) recently updated its treatment guidelines for the prophylaxis of CIN, with the objective of preserving hospital and ER resources for COVID-19 patients and maximizing protection for cancer patients against CIN development. This is designed to help necessitate healthcare interactions, and avoidance of hospital / ER visits will also minimize cancer patients' risk of contracting COVID-19. In light of these NCCN guideline updates, BeyondSpring initiated an Expanded Access Program to enable the use of Plinabulin by oncologists to better protect cancer patients against CIN with the use of myelosuppressive chemotherapies under the current COVID-19 challenges.

    Dr. Emad Ibrahim enrolled the first patient under this EAP at Redlands Community Hospital in California:

    • This involved a patient with breast cancer receiving standard-of-care chemotherapy (AC). The patient developed Grade 4 neutropenia in Cycle 1 despite the use of Pegfilgrastim at 6mg.
    • When the patient completed Cycle 2 with the Plinabulin and Pegfilgrastim combination, the patient did not develop Grade 4 neutropenia. 

    "The recent updates to the NCCN guidelines aim to protect cancer patients from developing CIN in the most effective way possible and enable the healthcare system to reserve precious resources for COVID-19 patients," said Ramon Mohanlal, BeyondSpring's Chief Medical Officer and Executive Vice President, Research and Development. "In our CIN studies, Plinabulin, in combination with Pegfilgrastim, provided superior protection against CIN, compared to the standard of care alone. The observation in this first EAP patient who completely avoided Grade 4 CIN when given Plinabulin and Pegfilgrastim is a significant achievement for us. At BeyondSpring, we strive to play our part in serving patients and healthcare providers to the highest degree while working through the many challenges imposed by COVID-19." 

    Preventing CIN during chemotherapy is extremely important, as this will enable cancer patients to receive the full regimen of chemotherapy and achieve treatment goals. The onset of CIN is the No. 1 reason for treatment modifications, such as downgrading the strength of chemotherapy or stopping chemotherapy altogether. When a patient develops CIN, the treating physician is required to delay the next round of chemotherapy until a patient's white blood cell count recovers. These changes can have a profoundly negative impact on patient outcomes.

    For more information on BeyondSpring's Plinabulin Expanded Access Program, please visit www.beyondspringpharma.com/EAP/. Supplies may be limited.

    If you are a physician in the U.S. who would like to request Plinabulin EAP access for your patient, please email .

    About BeyondSpring

    Headquartered in New York, BeyondSpring is a global, clinical-stage biopharmaceutical company focused on developing innovative immuno-oncology cancer therapies to improve clinical outcomes for patients with high unmet medical needs. BeyondSpring's first-in-class lead immune asset, Plinabulin, is a potent antigen-presenting cell (APC) inducer. It is currently in two Phase 3 clinical trials for two severely unmet medical needs indications: one is for the prevention of chemotherapy-induced neutropenia (CIN), the most frequent cause for a chemotherapy regimen dose's decrease, delay, downgrade or discontinuation, which can lead to suboptimal clinical outcomes. The other is for non-small cell lung cancer (NSCLC) treatment in EGFR wild-type patients. As a "pipeline drug," Plinabulin is in various I/O combination studies to boost PD-1 / PD-L1 antibody anti-cancer effects. In addition to Plinabulin, BeyondSpring's extensive pipeline includes three pre-clinical immuno-oncology assets and a drug discovery platform dubbed "molecular glue" that uses the protein degradation pathway. 

    About Plinabulin

    Plinabulin, BeyondSpring's lead asset, is a differentiated immune and stem cell modulator. Plinabulin is currently in late-stage clinical development to increase overall survival in cancer patients, as well as to alleviate chemotherapy-induced neutropenia (CIN). The durable anticancer benefits of Plinabulin have been associated with its effect as a potent antigen-presenting cell (APC) inducer (through dendritic cell maturation) and T-cell activation (Chem and Cell Reports, 2019). Plinabulin's CIN data highlights the ability to boost the number of hematopoietic stem / progenitor cells (HSPCs), or lineage-/cKit+/Sca1+ (LSK) cells in mice. Effects on HSPCs could explain the ability of Plinabulin to not only treat CIN but also to reduce chemotherapy-induced thrombocytopenia and increase circulating CD34+ cells in patients.

    Cautionary Note Regarding Forward-Looking Statements

    This press release includes forward-looking statements that are not historical facts. Words such as "will," "expect," "anticipate," "plan," "believe," "design," "may," "future," "estimate," "predict," "objective," "goal," or variations thereof and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are based on BeyondSpring's current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, difficulties raising the anticipated amount needed to finance the Company's future operations on terms acceptable to the Company, if at all, unexpected results of clinical trials, delays or denial in regulatory approval process, results that do not meet our expectations regarding the potential safety, the ultimate efficacy or clinical utility of our product candidates, increased competition in the market, and other risks described in BeyondSpring's most recent Form 20-F on file with the U.S. Securities and Exchange Commission. All forward-looking statements made herein speak only as of the date of this release and BeyondSpring undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

    Media Contacts

    Caitlin Kasunich / Raquel Cona

    KCSA Strategic Communications

    212.896.1241 / 212.896.1276

    /

    View Full Article Hide Full Article
  2. NEW YORK, June 30, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the "Company" or "BeyondSpring") (NASDAQ:BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the Company presented clinical data on BeyondSpring's first-in-class, late-stage asset, Plinabulin, showing potent CD34+ progenitor cell mobilization from bone marrow, which has broad applications for stem cell-based therapies, gene therapy and regenerative medicine. These findings potentially add another indication to Plinabulin, which is known as a "pipeline in a drug." Dr. Ramon Mohanlal, BeyondSpring's Chief Medical Officer and Executive Vice President, Research and Development, presented this new…

    NEW YORK, June 30, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the "Company" or "BeyondSpring") (NASDAQ:BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the Company presented clinical data on BeyondSpring's first-in-class, late-stage asset, Plinabulin, showing potent CD34+ progenitor cell mobilization from bone marrow, which has broad applications for stem cell-based therapies, gene therapy and regenerative medicine. These findings potentially add another indication to Plinabulin, which is known as a "pipeline in a drug." Dr. Ramon Mohanlal, BeyondSpring's Chief Medical Officer and Executive Vice President, Research and Development, presented this new data as a poster at this year's ISSCR Annual Meeting.

    Current approved agents for CD34+ progenitor cell mobilization, such as G-CSFs or Plerixafor (CXCR4-antagonist), have many limitations.  While G-CSFs are highly effective in preventing chemotherapy-induced neutropenia (CIN), they come with severe side effects, such as bone pain and thrombocytopenia. To add, multiple doses of short-acting G-CSFs (up to six or seven) are often needed for the therapy to be effective. Plerixafor is also given by daily injections for four to five days and is a very expensive process and not as effective for CD34+ cells (American Health and Drug Benefits, 2012). 

    Additionally, G-CSFs are contra-indicated in Sickle Cell Disorder (SCD) patients undergoing gene therapy. This results in high rates of adverse events requiring hospitalization, including vaso-occlusive crises, multi-organ failure and even death (Chien, Haematologica 2018). Lastly, when side effects such as bone pain, leukocytosis (high white blood cell count) and / or myalgia (muscle pain) occur, a G-CSF dose is often reduced to 50 percent, which is less effective for CD34+ cell mobilization.

    Plinabulin is a novel and potent agent for the prevention of CIN and does not cause bone pain or thrombocytopenia.  Plinabulin is given as a single fixed dose (40mg) - as a 30-minute intravenous infusion - and has a mechanism of action independent from G-CSF of CXCR4.

    In BeyondSpring's PROTECTIVE-2 Phase 2 study, the team evaluated the effects of CD34+ cell mobilization through combining Plinabulin with the full dose of Pegfilgrastim (Peg) at 6mg and at lower doses of 3mg and 1.5mg in breast cancer patients receiving taxotere, doxorubicin and cyclophosphamide (TAC).

    • The data shows that combining Plinabulin with a low dose of Pegfilgrastim produces statistically significant CD34+ cell counts (p<0.03) and increases to values that are comparable to, or numerically higher than, the full dose of Pegfilgrastim alone under severe myelosuppressive conditions. 

    In BeyondSpring's PROTECTIVE-1 Phase 2 study, the Company previously reported that lung cancer patients receiving docetaxel who received a single dose of Plinabulin saw an increase of CD34+ counts to clinically and statistically significant (p<0.001) levels under myelosuppressive conditions (Blayney, ASH 2018).

    The above data presentation is available on the "Posters" page of BeyondSpring's website. Please click here for more information.

    "Plinabulin's mechanism of action for CD34+ cell mobilization, which is independent from G-CSFs or CXCR4, offers an important alternative to patients who do not adequately respond to these agents, including patients where G-CSFs are contra-indicated," said Dr. Mohanlal. "Stem cell-based applications, such as gene therapy, is bound to become the standard of care for SCD, for which Plinabulin is well-positioned for CD34+ cell mobilization, given that G-CSFs are contra-indicated for SCD patients. With more than 100,000 SCD patients in the U.S. alone, this represents a near-term opportunity for Plinabulin, along with other CD34+ progenitor cell applications."

    About BeyondSpring

    Headquartered in New York, BeyondSpring is a global, clinical-stage biopharmaceutical company focused on developing innovative immuno-oncology cancer therapies to improve clinical outcomes for patients with high unmet medical needs. BeyondSpring's first-in-class lead immune asset, Plinabulin, is a potent antigen-presenting cell (APC) inducer. It is currently in two Phase 3 clinical trials for two severely unmet medical needs indications: one is for the prevention of chemotherapy-induced neutropenia (CIN), the most frequent cause for a chemotherapy regimen dose's decrease, delay, downgrade or discontinuation, which can lead to suboptimal clinical outcomes. The other is for non-small cell lung cancer (NSCLC) treatment in EGFR wild-type patients. As a "pipeline drug," Plinabulin is in various I/O combination studies to boost PD-1 / PD-L1 antibody anti-cancer effects. In addition to Plinabulin, BeyondSpring's extensive pipeline includes three pre-clinical immuno-oncology assets and a drug discovery platform dubbed "molecular glue" that uses the protein degradation pathway.

    About Plinabulin

    Plinabulin, BeyondSpring's lead asset, is a differentiated immune and stem cell modulator. Plinabulin is currently in late-stage clinical development to increase overall survival in cancer patients, as well as to alleviate chemotherapy-induced neutropenia (CIN). The durable anticancer benefits of Plinabulin have been associated with its effect as a potent antigen-presenting cell (APC) inducer (through dendritic cell maturation) and T-cell activation (Chem and Cell Reports, 2019). Plinabulin's CIN data highlights the ability to boost the number of hematopoietic stem / progenitor cells (HSPCs), or lineage-/cKit+/Sca1+ (LSK) cells in mice. Effects on HSPCs could explain the ability of Plinabulin to not only treat CIN but also to reduce chemotherapy-induced thrombocytopenia and increase circulating CD34+ cells in patients.

    Cautionary Note Regarding Forward-Looking Statements

    This press release includes forward-looking statements that are not historical facts. Words such as "will," "expect," "anticipate," "plan," "believe," "design," "may," "future," "estimate," "predict," "objective," "goal," or variations thereof and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are based on BeyondSpring's current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, difficulties raising the anticipated amount needed to finance the Company's future operations on terms acceptable to the Company, if at all, unexpected results of clinical trials, delays or denial in regulatory approval process, results that do not meet our expectations regarding the potential safety, the ultimate efficacy or clinical utility of our product candidates, increased competition in the market, and other risks described in BeyondSpring's most recent Form 20-F on file with the U.S. Securities and Exchange Commission. All forward-looking statements made herein speak only as of the date of this release and BeyondSpring undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

    Media Contacts

    Caitlin Kasunich / Raquel Cona

    KCSA Strategic Communications

    212.896.1241 / 212.896.1276

    /

    View Full Article Hide Full Article
  3. Research Presented at 2020 AACR Virtual Annual Meeting

    The Triple I/O Combination of Plinabulin, Anti-PD-1 and Radiation Achieved a 100 Percent Complete Response in Anti-PD-1 Non-responsive Animal Model

    Triple I/O Combination to Be Administered to Patients Who Failed I/O in Second Half of 2020

    NEW YORK, June 23, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the "Company" or "BeyondSpring") (NASDAQ:BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology (I/O) therapies, today announced new preclinical research findings that indicate BeyondSpring's lead asset, Plinabulin, enhances immuno-radiotherapy for cancer patients. The results of this preclinical study was highlighted in a poster presentation titled…

    Research Presented at 2020 AACR Virtual Annual Meeting

    The Triple I/O Combination of Plinabulin, Anti-PD-1 and Radiation Achieved a 100 Percent Complete Response in Anti-PD-1 Non-responsive Animal Model

    Triple I/O Combination to Be Administered to Patients Who Failed I/O in Second Half of 2020

    NEW YORK, June 23, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the "Company" or "BeyondSpring") (NASDAQ:BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology (I/O) therapies, today announced new preclinical research findings that indicate BeyondSpring's lead asset, Plinabulin, enhances immuno-radiotherapy for cancer patients. The results of this preclinical study was highlighted in a poster presentation titled, "Plinabulin, a microtubule destabilizing agent, improves tumor control by enhancing dendritic cell maturation and CD8 T cell infiltration in combination with immunoradiotherapy," at this year's American Association for Cancer Research (AACR) Virtual Annual Meeting on June 22, 2020. 

    Based on these preclinical findings, including a 100% complete response of the triple I/O combination of Plinabulin, anti-PD-1, and radiation in a PD-1 antibody non-responsive model, the compound is being advanced toward a Phase 1 clinical trial in patients who failed or progressed on PD-1 / PD-L1 antibody treatments. Principal investigator Steven H. Lin, M.D., Ph.D., associate professor of radiation oncology at The University of Texas MD Anderson Cancer Center, presented the research data.

    "The experiments from my lab demonstrated that Plinabulin treatment in murine cancer models leads to activation of antigen-presenting dendritic cells," said Dr. Lin. "The combination therapy with Plinabulin, anti-PD-1 therapy and radiation therapy further activated the immune system, resulting in increased T-cell activation, which is associated with increased tumor regressions."

    Additional data highlights include:

    • Preclinical effectiveness: The triple I/O combination of Plinabulin, anti-PD-1 and radiation achieved a 100 percent complete response in a breast cancer model that is not responsive to PD-1 antibody alone.
    • Sequential benefit: Plinabulin's effects on dendritic cell maturation are greater when administered after each dose of fractionated radiotherapy, compared to administration before radiation, or administration only once after the first dose of radiotherapy.
    • Abscopal effect: The Plinabulin triple combination anticancer effects in both irradiated and non-irradiated tumors in the same mice indicate the activation of a systemic anticancer immune response.  Notably, CD8 cell levels in the non-irradiated tumors were almost double in the triple combination group compared to anti-PD-1 and radiation alone.
    • Dendritic cell MHCII up-regulation and T-cell tumor infiltration: Plinabulin triple combination significantly increased dendritic cell MHCII expression and T-cell infiltration in the tumor.
    • I/O mechanism: AP-1 and NF-kB molecular pathways are crucial in the Plinabulin-induced maturation of dendritic cells.

    The above data presentation is available on the Posters page of the BeyondSpring's website at: https://www.beyondspringpharma.com/conferences/list.aspx?lcid=3.

    Peer-reviewed 2019 publications in Chem and Cell Reports demonstrated that Plinabulin is differentiated from all other tubulin-targeted agents through its binding site and kinetics and is among the most potent agents that induce dendritic cell maturation. Dendritic cells are key immune cell types in the activation of the immune system against cancer cells, but currently approved immuno-oncology agents, such as antibodies to PD-1, only take the brakes off of T-cells without activating antigen-presenting cells that stimulate T-cells to attack foreign proteins expressed by cancer cells. 

    "We believe that the activation of dendritic cells is a key to unlocking the next boost to the efficacy of immuno-oncology agents," said Dr. James Tonra, BeyondSpring's Chief Scientific Officer. "Activated dendritic cells present foreign tumor antigens to T-cells to induce cancer-directed immune attacks. Thus, adding this critical step of dendritic cell activation in the immune cascade to the established effects of immune checkpoint inhibition therapies is expected to increase overall anti-cancer efficacy in the clinic. Our anti-cancer strategy was to activate dendritic cells and T-cells, in combination with checkpoint inhibition and to add onto the benefits of neoantigen generation and immune activation from radiotherapy, as Plinabulin serves as the key to reverse the tumor non-response to PD-1/PD-L1 antibodies. The data strongly indicates that this triple combination has enough potential to move into clinical testing to help patients who failed or had progressed on anti-PD-1/PD-L1 targeted therapy, a severely unmet medical need."

    About BeyondSpring

    BeyondSpring is a global, clinical-stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies. BeyondSpring's lead asset, first-in-class agent Plinabulin as an immune and stem cell modulator, is in a Phase 3 global clinical trial as a direct anticancer agent in the treatment of non-small cell lung cancer (NSCLC) and two Phase 3 clinical programs in the prevention of chemotherapy-induced neutropenia (CIN). BeyondSpring has strong R&D capabilities with a robust pipeline in addition to Plinabulin, including three immuno-oncology assets and a drug discovery platform using the ubiquitination degradation pathway. The Company also has a seasoned management team with many years of experience bringing drugs to the global market.

    About Plinabulin

    Plinabulin, BeyondSpring's lead asset, is a differentiated immune and stem cell modulator. Plinabulin is currently in late-stage clinical development to increase overall survival in cancer patients, as well as to alleviate chemotherapy-induced neutropenia (CIN). The durable anticancer benefits of Plinabulin have been associated with its effect as a potent antigen-presenting cell (APC) inducer (through dendritic cell maturation) and T-cell activation (Chem and Cell Reports, 2019). Plinabulin's CIN data highlights the ability to boost the number of hematopoietic stem / progenitor cells (HSPCs), or lineage-/cKit+/Sca1+ (LSK) cells in mice. Effects on HSPCs could explain the ability of Plinabulin to not only treat CIN but also to reduce chemotherapy-induced thrombocytopenia and increase circulating CD34+ cells in patients.

    Cautionary Note Regarding Forward-Looking Statements

    This press release includes forward-looking statements that are not historical facts. Words such as "will," "expect," "anticipate," "plan," "believe," "design," "may," "future," "estimate," "predict," "objective," "goal," or variations thereof and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are based on BeyondSpring's current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, difficulties raising the anticipated amount needed to finance the Company's future operations on terms acceptable to the Company, if at all, unexpected results of clinical trials, delays or denial in regulatory approval process, results that do not meet our expectations regarding the potential safety, the ultimate efficacy or clinical utility of our product candidates, increased competition in the market, and other risks described in BeyondSpring's most recent Form 20-F on file with the U.S. Securities and Exchange Commission. All forward-looking statements made herein speak only as of the date of this release and BeyondSpring undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

    Media Contacts

    Caitlin Kasunich / Raquel Cona

    KCSA Strategic Communications

    212.896.1241 / 212.896.1276

    /

    View Full Article Hide Full Article
  4. NEW YORK, June 19, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the "Company" or "BeyondSpring") (NASDAQ:BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced the pricing of its public offering of 1,930,000 ordinary shares at a public offering price of $13.00 per share. The Company also announced the sale of an aggregate of 384,615 ordinary shares at the public offering price to entities affiliated with Decheng Capital in a separate private placement transaction. The gross proceeds from the public offering and the private placement are expected to be approximately $30.1 million, before deducting underwriting discounts and commissions and other offering expenses…

    NEW YORK, June 19, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the "Company" or "BeyondSpring") (NASDAQ:BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced the pricing of its public offering of 1,930,000 ordinary shares at a public offering price of $13.00 per share. The Company also announced the sale of an aggregate of 384,615 ordinary shares at the public offering price to entities affiliated with Decheng Capital in a separate private placement transaction. The gross proceeds from the public offering and the private placement are expected to be approximately $30.1 million, before deducting underwriting discounts and commissions and other offering expenses. The underwriters have a 30-day option to purchase from the Company up to an additional 289,500 ordinary shares at the public offering price. The Company intends to use the net proceeds of this offering and the private placement to support the commercialization of Plinabulin, continued clinical and pre-clinical development and for general corporate purposes. The offering is expected to close on June 23, 2020 and the private placement is expected to close on July 2, 2020, each subject to satisfaction of customary closing conditions.  

    Jefferies and William Blair are acting as joint book-running managers for the offering. Nomura is acting as lead manager for the offering. H.C. Wainwright & Co. is acting as co-manager for the offering.

    The offering is being made pursuant to the Company's existing shelf registration statement, which was filed with the U.S. Securities and Exchange Commission (the "SEC") on October 15, 2019 and became effective on October 21, 2019. The offering of these securities was made only by means of a prospectus and a related prospectus supplement, which will be filed with the SEC. Copies of the prospectus and prospectus supplement related to this offering may be obtained, when available, from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by calling (877) 821-7388, or by emailing or William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, Illinois 60606, or by calling (800) 621-0687, or by emailing .

    This press release shall not constitute an offer to sell or the solicitation of an offer to buy the shares or any other securities, nor shall there be any sale of such shares or any other securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

    About BeyondSpring

    BeyondSpring is a global, clinical-stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies. BeyondSpring's lead asset, first-in-class agent Plinabulin, is in a Phase 3 global clinical trial as a direct anticancer agent in the treatment of non-small cell lung cancer (NSCLC) and two Phase 3 clinical programs in the prevention of chemotherapy-induced neutropenia (CIN). BeyondSpring has strong R&D capabilities with a robust pipeline in addition to Plinabulin, including three immuno-oncology assets and a drug discovery platform using the ubiquitination degradation pathway. The Company also has a seasoned management team with many years of experience bringing drugs to the global market. BeyondSpring is headquartered in New York City

    Cautionary Note Regarding Forward-Looking Statements

    This press release includes forward-looking statements that are not historical facts. Words such as "will," "expect," "anticipate," "plan," "believe," "design," "may," "future," "estimate," "predict," "objective," "goal," or variations thereof and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are based on BeyondSpring's current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Certain of the statements made in this press release are forward-looking, such as those, among others, relating to BeyondSpring's expectations regarding the completion of the proposed offering and the private placement. No assurance can be given that the offering or the private placement discussed above will be consummated, or that the net proceeds of the offering or the private placement will be used as indicated. Consummation of the offering and the private placement and the application of the net proceeds of the offering and the private placement are subject to numerous possible events, factors and conditions, many of which are beyond the control of the Company and not all of which are known to it, including, without limitation, market conditions and those described under the heading "Risk Factors" in the Company's Annual Report on Form 20-F for the year ended December 31, 2019, as updated by those risk factors included in the Company's subsequent filings under the Securities Exchange Act of 1934, as amended, which can be accessed at the SEC's website at www.sec.gov. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, difficulties raising the anticipated amount needed to finance the Company's future operations on terms acceptable to the Company, if at all, unexpected results of clinical trials, delays or denial in regulatory approval process, results that do not meet its expectations regarding the potential safety, the ultimate efficacy or clinical utility of its product candidates, increased competition in the market, the impact of widespread health developments, including the recent COVID-19 pandemic, and the responses thereto, which could materially and adversely affect, among other things, enrollment of patients in the Company's clinical trials and its expected timeline for data readouts of its clinical trials and certain regulatory filings for its product candidates, unexpected changes to estimates of its expenses, future revenues and capital requirements, and other risks described in BeyondSpring's most recent Form 20-F on file with the SEC. All forward-looking statements made herein speak only as of the date of this release and BeyondSpring undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

    CONTACT:

    Media & Investor Relations:

    Scott Eckstein / Caitlin Kasunich

    KCSA Strategic Communications

    212.896.1210 / 212.896.1241

    /  

    View Full Article Hide Full Article
  5. NEW YORK, June 18, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the "Company" or "BeyondSpring") (NASDAQ:BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced the launch of an underwritten public offering of its ordinary shares. The Company also expects to grant the underwriters an option to purchase up to an additional 15% of the ordinary shares being offered. The Company also intends to sell additional ordinary shares to entities affiliated with Decheng Capital in a separate private placement transaction. The Company intends to use the net proceeds of this offering and the private placement to support the commercialization of Plinabulin, continued clinical and…

    NEW YORK, June 18, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the "Company" or "BeyondSpring") (NASDAQ:BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced the launch of an underwritten public offering of its ordinary shares. The Company also expects to grant the underwriters an option to purchase up to an additional 15% of the ordinary shares being offered. The Company also intends to sell additional ordinary shares to entities affiliated with Decheng Capital in a separate private placement transaction. The Company intends to use the net proceeds of this offering and the private placement to support the commercialization of Plinabulin, continued clinical and pre-clinical development and for general corporate purposes.

    Jefferies and William Blair will be acting as joint book-running managers for the offering. The offering is subject to market and other conditions and may not be completed on the terms described or at all.

    The offering is being made pursuant to the Company's existing shelf registration statement, which was filed with the U.S. Securities and Exchange Commission (the "SEC") on October 15, 2019 and became effective on October 21, 2019. The offering of these securities is being made only by means of a prospectus and a related prospectus supplement, which will be filed with the SEC. Copies of the prospectus and prospectus supplement related to this offering may be obtained, when available, from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by calling (877) 821-7388, or by emailing or William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, Illinois 60606, or by calling (800) 621-0687, or by emailing .

    This press release shall not constitute an offer to sell or the solicitation of an offer to buy the shares or any other securities, nor shall there be any sale of such shares or any other securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

    About BeyondSpring

    BeyondSpring is a global, clinical-stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies. BeyondSpring's lead asset, first-in-class agent Plinabulin, is in a Phase 3 global clinical trial as a direct anticancer agent in the treatment of non-small cell lung cancer (NSCLC) and two Phase 3 clinical programs in the prevention of chemotherapy-induced neutropenia (CIN). BeyondSpring has strong R&D capabilities with a robust pipeline in addition to Plinabulin, including three immuno-oncology assets and a drug discovery platform using the ubiquitination degradation pathway. The Company also has a seasoned management team with many years of experience bringing drugs to the global market. BeyondSpring is headquartered in New York City.

    Cautionary Note Regarding Forward-Looking Statements

    This press release includes forward-looking statements that are not historical facts. Words such as "will," "expect," "anticipate," "plan," "believe," "design," "may," "future," "estimate," "predict," "objective," "goal," or variations thereof and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are based on BeyondSpring's current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Certain of the statements made in this press release are forward-looking, such as those, among others, relating to BeyondSpring's expectations regarding the completion of the proposed offering. No assurance can be given that the offering discussed above will be consummated, or that the net proceeds of the offering will be used as indicated. Consummation of the offering and the application of the net proceeds of the offering are subject to numerous possible events, factors and conditions, many of which are beyond the control of the Company and not all of which are known to it, including, without limitation, market conditions and those described under the heading "Risk Factors" in the Company's Annual Report on Form 20-F for the year ended December 31, 2019, as updated by those risk factors included in the Company's subsequent filings under the Securities Exchange Act of 1934, as amended, which can be accessed at the SEC's website at www.sec.gov. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, difficulties raising the anticipated amount needed to finance the Company's future operations on terms acceptable to the Company, if at all, unexpected results of clinical trials, delays or denial in regulatory approval process, results that do not meet its expectations regarding the potential safety, the ultimate efficacy or clinical utility of its product candidates, increased competition in the market, the impact of widespread health developments, including the recent COVID-19 pandemic, and the responses thereto, which could materially and adversely affect, among other things, enrollment of patients in the Company's clinical trials and its expected timeline for data readouts of its clinical trials and certain regulatory filings for its product candidates, unexpected changes to estimates of its expenses, future revenues and capital requirements, and other risks described in BeyondSpring's most recent Form 20-F on file with the SEC. All forward-looking statements made herein speak only as of the date of this release and BeyondSpring undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

    CONTACT:

    Media & Investor Relations:

    Scott Eckstein / Caitlin Kasunich

    KCSA Strategic Communications

    212.896.1210 / 212.896.1241

    /

    View Full Article Hide Full Article
View All BeyondSpring Inc. News